Chondrosarcoma
MONDO:0008977A malignant cartilaginous matrix-producing mesenchymal neoplasm arising from the bone and soft tissue. It usually affects middle-aged to elderly adults. The pelvic bones, ribs, shoulder girdle, and long bones are the most common sites of involvement. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion.
Also known as: chondrosarcoma, chondrosarcoma (disease), chondrosarcoma, malignant, chondrosarcoma, somatic mutation, chondrosarcoma of bone, primary chondrosarcoma of the bone
2805 clinical trials for this condition and its sub-types, 39 tagged with Chondrosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Chondrosarcoma
-
Bone chondrosarcoma 1 trial · 10 incl. sub-types
3 sub-types
- Dedifferentiated chondrosarcoma 9 trials
- Clear cell chondrosarcoma 3 trials
- Periosteal chondrosarcoma 0 trials
-
Mesenchymal chondrosarcoma 4 trials
2 sub-types
- Adult mesenchymal chondrosarcoma 0 trials
- Pediatric mesenchymal chondrosarcoma 0 trials
-
Myxoid chondrosarcoma 2 trials
2 sub-types
- Adult myxoid chondrosarcoma 0 trials
- Pediatric myxoid chondrosarcoma 0 trials
-
Localized chondrosarcoma 0 trials
-
New drug cocktail targets rare bone cancer that spreads
Disease control OngoingThis study tests two drug combinations (belinostat plus either guadecitabine or ASTX727) in 19 adults with a rare bone cancer called chondrosarcoma that has spread or cannot be removed surgically. The goal is to see if the drugs can shrink tumors or stop them from growing. Partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for rare bone cancer? drug shows promise in early trial
Disease control OngoingThis phase 2 trial tested vismodegib, a pill that targets a specific growth pathway, in 45 people with advanced chondrosarcoma (a rare bone cancer). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had to have measurable disease and no m…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a cancer immunotherapy drug shrink rare sarcomas?
Disease control OngoingThis phase 2 trial tests the drug atezolizumab in 27 people with chondrosarcoma or clear cell sarcoma that cannot be removed by surgery or has spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal is to see if the drug can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Voice box transplant trial hopes to give speech back to patients
Disease control PausedThis study tests whether transplanting a donor voice box (larynx) can safely restore voice, swallowing, and breathing in people with severe larynx damage or who have had their larynx removed. Ten adults will receive the transplant and be followed for five years. The trial is curr…
Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New targeted pill takes on Hard-to-Treat cancers with IDH mutations
Disease control OngoingThis early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug duo takes on rare sarcomas
Disease control OngoingThis phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their t…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New antibody drug shows promise for rare bone cancer
Disease control OngoingThis phase 2 trial tests a drug called INBRX-109 in people with a rare bone cancer (conventional chondrosarcoma) that cannot be removed by surgery or has spread. The drug is a lab-made antibody designed to kill cancer cells. About 206 participants will receive either INBRX-109 or…
Phase 2 • Sponsor: Inhibrx Biosciences, Inc • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Experimental drug tazemetostat offered to patients with rare, aggressive tumors
Disease control Expanded access (ended)This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…
Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Precision proton beams take aim at rare bone cancers
Disease control OngoingThis study tests a precise type of proton radiation (IMPT) for people with chordoma or chondrosarcoma in the spine, sacrum, or skull base. The goal is to control the tumor while reducing damage to healthy tissue. Some participants may also have surgery. The study includes 64 adul…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control OngoingThis study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare bone cancer: targeted drug AG-120 tested in small trial
Disease control OngoingThis study tests whether the drug AG-120 can safely slow or stop the growth of a rare bone cancer called chondrosarcoma that has a specific IDH1 gene mutation. Six adults with advanced or recurrent grade 2 or 3 chondrosarcoma will receive the drug. The main goal is to see how lon…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Proton beam therapy takes aim at rare skull base cancer
Disease control OngoingThis phase 2 trial is testing whether proton beam therapy, a precise form of radiation, can control skull base chondrosarcoma after surgery. Fifteen participants who have had maximal surgical removal of their tumor will receive daily proton treatments for about 7 weeks. The study…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a common bone drug help fight a rare cancer?
Disease control OngoingThis phase 1b trial is testing whether giving zoledronic acid, a drug usually used for bone thinning, before surgery can help people with chondrosarcoma, a rare bone cancer. Seventeen adults with any grade of the disease that can be surgically removed will receive the drug and th…
Phase 1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
How do patients feel after Nose-Based brain surgery? new study aims to find out
Knowledge-focused OngoingThis study follows 400 patients for two years after they have endoscopic endonasal skull base surgery (surgery through the nose to reach the base of the skull). The goal is to measure their quality of life and nose function using standard questionnaires. It does not test a new tr…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Rare bone tumor under the microscope: can we predict its behavior?
Knowledge-focused OngoingThis study gathers information from 77 Italian patients with a rare, low-grade bone tumor called clear cell chondrosarcoma. Researchers will review medical records, imaging, and tissue samples to find patterns that might predict whether the tumor will come back or spread. The goa…
Sponsor: Istituto Ortopedico Rizzoli • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC